Selecting of probiotics with GLP-1 enhancing ability to attenuate hyperglycemia in vitro and in vivo
碩士 === 國立臺灣大學 === 動物科學技術學研究所 === 102 === Type 1 diabetes (T1D) is an autoimmune disease, which characterized by progressive dysfunction of pancreatic β cell and loss in β cell mass. The disease generally results in insulin deficiency and hyperglycemia. Glucagon-like peptide-1 (GLP-1) is a gut hormon...
Main Authors: | Shih-Hung Wei, 魏士弘 |
---|---|
Other Authors: | Ming-Ju Chen |
Format: | Others |
Language: | zh-TW |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/78895405004602669408 |
Similar Items
-
Selecting probiotics with the abilities of enhancing GLP-1 to mitigate the progression of type 1 diabetes in vitro and in vivo
by: Shih-Hung Wei, et al.
Published: (2015-10-01) -
Selection of uremic toxin-reducing probiotics in vitro and in vivo
by: Chen-Yu Fang, et al.
Published: (2014-03-01) -
Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis
by: Shu Meguro, et al.
Published: (2014-01-01) -
Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
by: Richard A. Manfready, et al.
Published: (2021-07-01) -
Exploring the GLP-1–GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
by: Elin Manell, et al.
Published: (2021-08-01)